Berlin Declaration" by IFPMA
IFPMA has issued the "Berlin Declaration" as its vision for achieving equitable access to vaccines and therapeutics in future pandemics.
IFPMA commends the 2022 German G7 commitment to better prepare for and respond to pandemics, and Germany's leadership as G7 chair, in the "Berlin Declaration," a vision for achieving equitable access to vaccines and therapeutics in a future pandemic. We are pleased to announce that the Berlin Declaration was released on July 19, 2022.
The Declaration sets out an approach for the pharmaceutical industry to draw on lessons learned from COVID-19 to help the world prepare for and respond to pandemics in a more equitable manner. It focuses on three key areas: (1) promoting innovation in pandemic preparedness, (2) strengthening manufacturing capacity to supply pandemic products globally, and (3) advance planning to ensure equitable access to pandemic products. It also proposes to the G7, G20, and other world leaders a framework to further improve the provision of vaccines, treatments, and diagnostics to priority populations in low-income countries.
A prerequisite for the success of this Declaration is that the health care systems of low-income countries are further prepared to accept and supply vaccines and therapeutics, and that high-income countries provide the necessary political and financial support. The Declaration also emphasizes the need for a strong innovation ecosystem based on intellectual property rights and the elimination of trade barriers to exports.
The Berlin Declaration is available on the IFPMA website.